scholarly journals Breast Uptake of Radio-iodine in Differentiated Thyroid Cancer

2020 ◽  
pp. 1-4
Author(s):  
Kanchan Kulkarni ◽  
Kanchan Kulkarni
Keyword(s):  
Thyroid Cancer ◽  
Breast Tissue ◽  
Differentiated Thyroid Cancer ◽  
Absorbed Dose ◽  
Radioiodine Uptake ◽  
Breast Malignancy

Radioiodine is often seen to accumulate within breast tissue in patients with differentiated thyroid cancer. Although the risk of secondary breast malignancy in patients with differentiated thyroid cancer treated with radioiodine is controversial, the identification and reduction of this uptake is prudent to minimize the radiation absorbed dose to the breast tissue. This article reviews the literature describing the etiology, frequency and patterns of radioiodine uptake in breast tissue. Approaches and techniques to help minimize the radioiodine uptake in lactating and nonlactating breasts are presented.

Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients

2015 ◽  
Vol 54 (03) ◽  
pp. 137-143 ◽  
Author(s):  
A.-S. Moldovan ◽  
M. Ruhlmann ◽  
R. Görges ◽  
A. Bockisch ◽  
S. Rosenbaum-Krumme ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Absorbed Dose ◽  
Thyroid Remnant ◽  
Remnant Ablation ◽  
Dose Threshold ◽  
131I Activity ◽  
Pet Ct ◽  
Absorbed Radiation Dose

SummaryAim: A theoretical dosimetry-based model was applied to estimate the lowest effective radioiodine activity for thyroid remnant ablation of low-risk differentiated thyroid cancer patients. Patients, methods: The model is based on the distribution of the absorbed (radiation) dose per administered radioiodine activity and the absorbed dose threshold of 300 Gy for thyroid remnants, the level believed to destroy most thyroid remnants. For this purpose, 124I PET/CT images of 49 thyroid-ectomised patients were retrospectively analysed to measure the distribution of the (average) absorbed doses to thyroid remnant per administered 131I activity. The fraction of thyroid remnants that received at least 300 Gy was determined for standard activities between 0.37 and 5.55 GBq. The lower activity was considered to be equally effective to that obtained with higher activity if the (absolute) fraction difference was below 5%. Results: A total of 62 thyroid remnants were included. The medians and ranges (in parentheses) for the absorbed dose per unit 131I activity were 359 Gy/GBq (34 to 1825 Gy/ GBq). The fractions of thyroid remnants receiving more than 300 Gy at different therapy activities (within parentheses) were 60% (1.11 GBq), 76% (1.85 GBq), 79% (2.22 GBq), and 81–82% for activities between 2.59 and 3.70 GBq. The therapy activity of 1.11 GBq is considerably less effective than that of 1.85 or 2.22 GBq; therapy activities were equally effective in the range between 2.22 to 3.70 GBq. Conclusion: On the basis of the model and the patients' data included, the lowest effective therapy activity appears to be approximately 2.2 GBq to ablate thyroid remnants. The results of this study may help to guide the design of prospective clinical studies.

Expression of the sodium iodide symporter in differentiated thyroid cancer

2005 ◽  
Vol 44 (03) ◽  
pp. 86-96 ◽  
Author(s):  
G. Schmitz ◽  
L. Füzesi ◽  
J. Struck ◽  
U. Siefker ◽  
A. Hamann ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Sodium Iodide ◽  
Primary Tumour ◽  
Sodium Iodide Symporter ◽  
Radioiodine Uptake ◽  
Imaging Results ◽  
Group 2 ◽  
Radionuclide Uptake ◽  
Group 1

Summary Aim: Molecular analysis of the expression of the sodium iodide symporter (NIS) in 32 patients with differentiated thyroid cancer (DTC) and correlation with scintigraphic findings (131I,123I) in 19 (59.4%) of them. Patients, methods: NIS expression of 27 primary tumours, 13 lymphnodes and 18 distant metastases was determined by immunostaining using a murine monoclonal anti-NIS-antibody. NIS expression and radionuclide uptake of metastases were analysed by a semiquantitative visual score. Patients were divided into two subgroups: Group 1 (n = 8 patients): indirect correlation of radioiodine uptake (RIU) of subsequent metastases with NIS expression of 7 primary tumours and 3 metastases; Group 2 (n=11 patients): direct correlation of radionuclide uptake with NIS expression of 19 metastases which were excised after imaging. Results: 49 of 58 specimens (84.5%) were NIS-positive. A preserved NIS-expression was found in 12 primary tumours and 8 of 10 (80%) synchrone and 6 of 7 (85.7%) metachrone metastases. Group 1 revealed a 100% positive predictive value (PPV) of a preserved NIS expression in the primary tumour regarding radioiodine uptake in metastases while a lack of NIS expression in the primary tumor did not reliable predict a loss of the metastases’ ability to concentrate radioiodine. In group 2, only 11 of 19 (57.9%) specimens showed a concordant NIS expression and RIU whereas in the remaining 8 cases without visible RIU NIS expression was still present. Conclusions: NIS expression of the primary tumour and metastases in DTC is usually well preserved. We found a positive correlation between NIS expression of the primary and metastatic tissue but could not identify such well correspondence between NIS expression and the RIU of subsequent metastases.

Radioiodine uptake in a renal cyst mimicking a metastasis in a patient affected by differentiated thyroid cancer: case report and review of the literature

2014 ◽  
Vol 28 (5) ◽  
pp. 472-476 ◽  
Author(s):  
Alfredo Campennì ◽  
Rosaria M. Ruggeri ◽  
Salvatore Giovinazzo ◽  
Alessandro Sindoni ◽  
Domenico Santoro ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Case Report ◽  
Differentiated Thyroid Cancer ◽  
Renal Cyst ◽  
Cancer Case ◽  
Review Of The Literature ◽  
Radioiodine Uptake

scholarly journals Advances in Functional Imaging of Differentiated Thyroid Cancer

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4748
Author(s):  
Michele Klain ◽  
Emilia Zampella ◽  
Carmela Nappi ◽  
Emanuele Nicolai ◽  
Raffaele Ambrosio ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Functional Imaging ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Radioiodine Uptake ◽  
Pet Ct ◽  
Diagnostic Management ◽  
18F Fdg ◽  
Fdg Pet Ct

The present review provides a description of recent advances in the field of functional imaging that takes advantage of the functional characteristics of thyroid neoplastic cells (such as radioiodine uptake and FDG uptake) and theragnostic approach of differentiated thyroid cancer (DTC). Physical and biological characteristics of available radiopharmaceuticals and their use with state-of-the-art technologies for diagnosis, treatment, and follow-up of DTC patients are depicted. Radioactive iodine is used mostly with a therapeutic intent, while PET/CT with 18F-FDG emerges as a useful tool in the diagnostic management and complements the use of radioactive iodine. Beyond 18F-FDG PET/CT, other tracers including 124I, 18F-TFB and 68Ga-PSMA, and new methods such as PET/MR, might offer new opportunities in selecting patients with DTC for specific imaging modalities or treatments.

Sign in / Sign up

Export Citation Format

Share Document